OBALON THERPTCS Company Profile (NASDAQ:OBLN)

OBALON THERPTCS trades on the NASDAQ under the ticker symbol "OBLN."

OBALON THERPTCS (NASDAQ:OBLN) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The company earned $1.96 million during the quarter, compared to analysts' expectations of $1.77 million. OBALON THERPTCS had a negative return on equity of 108.07% and a negative net margin of 566.87%. View OBALON THERPTCS's Earnings History.

OBALON THERPTCS is scheduled to release their next quarterly earnings announcement on Friday, November, 10th 2017. View Earnings Estimates for OBALON THERPTCS.

4 analysts have issued 1 year price objectives for OBALON THERPTCS's stock. Their forecasts range from $6.00 to $20.00. On average, they expect OBALON THERPTCS's stock price to reach $15.25 in the next twelve months. View Analyst Ratings for OBALON THERPTCS.

Here are some recent quotes from research analysts about OBALON THERPTCS stock:

• 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (8/16/2017)
• 2. Northland Securities analysts commented, "We are initiating coverage of Obalon Therapeutics with an Underperform rating / $6 PT. We are concerned that forward estimates are too high, the science is unclear, the logistical issues of 3- intragastric balloon (IGB) procedures remain, and finally, ponying up $8,000 or so in a cash-pay procedure for a 15 lb. weight loss makes this product more suitable for a wealthy, event-driven" motivated patient, therefore making the realistic TAM quite small." (6/21/2017)
• 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating following marketing meetings with management. We recently hosted two days of upbeat investor meetings with Obalon CEO Andy Rasdal as well as CFO Bill Plovanic. We came away from those meetings with a clearer understanding of investor sentiment as well as early commercial traction in the US launch." (5/18/2017)

Some companies that are related to OBALON THERPTCS include RTI Surgical (RTIX), ConforMIS (CFMS), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ), Trivascular Technologies (TRIV) and Uroplasty (UPI).

OBALON THERPTCS's management team includes the folowing people:

• Kim P Kamdar, Chairman of the Board
• Andrew Rasdal, President, Chief Executive Officer, Director
• William J. Plovanic, Chief Financial Officer
• Kelly Huang Ph.D., Chief Operating Officer
• Nooshin Hussainy, Vice President - Finance
• Steve Johnson, Vice President - Operations
• Matthew Norwood, Vice President of Sales
• Lisa Metzner, Vice President of Marketing
• Amy VandenBerg, Vice President - Regulatory and Clinical Affairs
• Donald Young, Vice President of Quality Assurance

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Shares of OBALON THERPTCS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OBALON THERPTCS stock can currently be purchased for approximately $9.07.